API Montelukast Sodium Tablet Asthma Montelukast Sodium Powder Montelukast

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Montelukast
• Product Name: Montelukast
• Appearance: off White or White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Asthma
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 158966-92-8
• Mf: C35h36clno3s
• MW: 608.16507
• Density: 1.272
• Melting Point: 275.9 C
• Boiling Point: 750.5 C at 760 Mmhg
• Refractive Index: 1.677
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 2 Ton/Month

Product Description

API Montelukast Sodium Tablet Asthma Montelukast Sodium Powder Montelukast

 

Product Description

Product Details

Product Name	Montelukast
Appearance	Off white or white powder
CAS No.	158966-92-8
MF	C35H36ClNO3S
MW	608.16507

Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affect on the CysLT2 receptor.   In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression.Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.

Application & Function

Function
Montelukastis a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.It blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.
Application
Montelukast is used for a number of conditions including asthma, exercise induced bronchospasm, allergic rhinitis,primary dysmenorrhoea and urticaria.It is mainly used as a complementary therapy in adults in addition to inhaled corticosteroids, if they alone do not bring the desired effect.It is also used to prevent allergic reactions and asthma flare-ups during the administration of intravenous immunoglobulin.Montelukast is administered as montelukast sodium, with 5.2 mg of montelukast sodium being equivalent to 5 mg of montelukast.

Specification